Launched in 2022, InAdvance is a Dana-Farber strategic initiative designed to disrupt the historical cancer care model by bringing state-of-the-art early detection and precision intervention to people at higher risk of developing cancer. This integrated research-clinical model will accelerate understanding of precursor conditions that precede cancer and bring earlier interventions for patients more rapidly. This panel discussion will provide an exclusive overview of InAdvance from the initiative’s leaders.

Dana-Farber’s mission is evenly divided between cutting-edge, collaborative research and state-of-the-art patient care. ​As a direct result of this fully integrated approach, the Institute has a demonstrated track record of bringing discoveries from the laboratory bench to the patient’s bedside in record time. Central to this translational research model is the unparalleled philanthropic support that accelerates progress. Panelists will highlight the cost of research and how philanthropy impacts research and patient care and attracts further funding.

Welcome from Josh Bekenstein, Chairman of the Board

50 Years of Far-Reaching Influence: Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology*

While Dana-Farber has been leading the way for 75 years, during the last 50 years our renowned clinical fellowship program has attracted the brightest early career physicians, researchers, and nurse-scientists to Dana-Farber in their pursuit of specialized training opportunities in cancer medicine.  This panel will feature some of the successful graduates from this program who have gone on to lead influential careers in oncology throughout the country. They will discuss the legacy of Dana-Farber’s fellowship program and its impact on future oncologists.